China-based WuXi Biologics projected 16% revenue growth and 54% net profit increase for the first half of 2025 in a 24 July earnings preview, attributing gains to expanded capacity and operational efficiency under its Follow and Win the Molecule strategy. The company's gross margin improved by 3.6 percentage points year-on-year, with adjusted non-IFRS net profit rising 11%. Shares closed 3.8% higher at HKD 29.85 following the announcement, reflecting market optimism about the contract development and manufacturing organisation (CDMO) sector's recovery.

The performance aligns with broader CXO industry growth, as peers including WuXi AppTec and Asymchem Laboratories also reported strong H1 results. WuXi Biologics highlighted progress in its WuXiBody bispecific antibody (BsAb) and T-cell engager (TCE) platforms, which have generated over USD 2.5 billion in business development deals since 2023. Recent US regulatory pre-license inspections (PLI) at Wuxi facilities and commercial production launches in Ireland further support its global expansion. The company maintains its full-year guidance of 17-20% revenue growth for core operations.

According to PharmCube's NextBiopharm® database, WuXi Biologics has established collaborations with nearly 30 companies, including a number of Big Pharmas. Click here to request a free trial for NextBiopharm®.